Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00354107 · ClinicalTrials.gov registry record · Phase 1
Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00354107: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00354107 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00354107, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This phase I/II trial is studying the side effects and best dose of SGN-30 when given together with ifosfamide, carboplatin, and etoposide and to see how well they work in treating young patients with recurrent anaplastic large cell lymphoma. Drugs used in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as SGN-30, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them.
Interventions
- DRUG carboplatin
- DRUG etoposide
- DRUG ifosfamide
- DRUG therapeutic hydrocortisone
- BIOLOGICAL monoclonal antibody SGN-30
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2007-01 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00354107
The ClinicalTrials.gov registry entry for NCT00354107 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00354107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00354107 about?
NCT00354107 is a clinical study titled "Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma". This phase I/II trial is studying the side effects and best dose of SGN-30 when given together with ifosfamide, carboplatin, and etoposide and to see how well they work in treating young patients with recurrent anaplastic large cell lymphoma. Drugs used in chemotherapy, such as ifosfamide, carboplat...
What is the current status of trial NCT00354107?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2007-01. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00354107?
The interventions under investigation include: carboplatin (DRUG), etoposide (DRUG), ifosfamide (DRUG), therapeutic hydrocortisone (DRUG), monoclonal antibody SGN-30 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00354107?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.